Luciano Costa, MD, reviews recent data from the PERSEUS trial investigating the combination of daratumumab, bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients.
Updates in the Treatment of Newly Diagnosed Multiple Myeloma from ASH 2023
Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.
Larry Anderson, MD, goes over the recent data from the IsKia trial which investigated IsaKRd in pre-transplant induction and post-transplant consolidation in TE NDMM.
Three medical oncologists explore the influence of MRD negativity rates on treatment decisions and discover the ideal patient profile for quadruplet regimen.
Philippe Moreau, MD, discusses recent data from the IFM 2018 trial which evaluated Dara-KRd induction and consolidation plus double transplants in high risk, TE NDMM.
Experts dive into the complexities of defining and treating high-risk Multiple Myeloma (MM) and discuss the role of ASCT in newly diagnosed MM and weigh the considerations for recommending transplants, including insights on the selection criteria for tandem transplantations.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
FDA Approves Ziftomenib in R/R NPM1-Mutated Acute Myeloid Leukemia
3
Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research
4
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
5
